- Indication: front-line maintenance for HER2+ metastatic breast cancer after induction
- Combination: TUKYSA + trastuzumab + pertuzumab
- Trial: HER2CLIMB-05 Phase 3, randomized, double-blind, placebo-controlled
- Primary endpoint: investigator-assessed PFS
- Hr 0.64 (95% ci 0.51-0.80, p<0.0001)
- Median PFS: 24.9 months (TUKYSA arm) vs 16.3 months (placebo)
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card